基于网络药理学探究山慈菇-莪术对治疗胰腺癌的作用机制

摘要/Abstract

摘要： 目的通过网络药理学的方法寻找山慈菇-莪术药物组合治疗胰腺癌的有效作用机制。方法运用TCMSP数据库分析出山慈菇-莪术的主要活性成分和作用靶点,利用OMIM、TTD、GeneCards等在线数据库获得胰腺癌相关作用靶点;获取中药与疾病的交集靶点,以String数据库对共同靶点构建蛋白互作网络在线（PPI）分析,并筛选有效作用靶点;最后通过Cytoscape 3.7.2软件的ClueGO插件对共同靶点进行GO和KEGG的富集分析,并构建主要活性成分-交集靶点-信号通路的可视化网络。结果通过以上方法,筛选获得山慈菇-莪术治疗胰腺癌的作用成分共6种,核心作用靶点10个;富集分析山慈菇-莪术治疗胰腺癌涉及的主要生物过程,并主要调控4个信号通路。结论此次网络药理学研究表明,山慈菇-莪术可以通过β-谷甾醇等活性成分并调控PI3K-Akt信号通路等途径从而发挥治疗胰腺癌的作用,表明中医药治疗疾病具有多成分、多靶点、多通路的特点,具有临床应用价值。

关键词: 网络药理学, 山慈菇, 莪术, 胰腺癌, 靶点, 通路, 分子机制

Abstract: Objective To explore the molecular mechanism of pleurotus ostreatus-zedoary turmeric combination in the treatment of pancreatic cancer by means of network pharmacology. Methods The main active components and action targets of pleurotus ostreatus-zedoary were obtained by TCMSP database, the pancreatic cancer related targets were obtained by OMIM, TTD, GeneCards and other databases, the intersection targets of traditional Chinese medicine and disease were obtained, and the protein interaction network (PPI) was analyzed by String database, and the core targets were screened. Finally, the ClueGO plug-in of Cytoscape3.7.2 software is used to analyze the enrichment of intersection targets by GO and KEGG, and a visual network of active components-target-signal pathway of traditional Chinese medicine is constructed. Results Six active components of pleurotus ostreatus-zedoary in the treatment of pancreatic cancer were obtained and 10 core targets,enrichment analysis mainly involved in biological processes and 4 mainly regulated signaling pathways in cancer. Conclusion The research based on network pharmacology shows that pleurotus ostreatus-zedoary can play a role in the treatment of pancreatic cancer through active components such as β-sitosterol and regulating PI3K-Akt signaling pathway, indicating that traditional Chinese medicine has the characteristics of multi-components, multi-targets and multi-pathways, and has a certain value in clinical application.

Key words: network pharmacology, pleurotus ostreatus, zedoary, pancreatic cancer, targe, pathway, molecular mechanism

中图分类号:

R285.5

华雯, 杨诗雨, 陈牧文, 王怡仪, 陈俊. 基于网络药理学探究山慈菇-莪术对治疗胰腺癌的作用机制[J]. 中华养生保健, 2025, 43(5): 92-96.

HUA Wen, YANG Shi-yu, CHEN Mu-wen, WANG Yi-yi, CHEN Jun. Study on the Molecular Mechanism of Pleurotus Ostreatus-Zedoary Combination in the Treatment of Pancreatic Cancer Based on Network Pharmacology[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(5): 92-96.

参考文献

[1] 徐冬,杨飞,夏存冰.胰腺癌免疫治疗的应用现状与展望[J].中国肿瘤外科杂志,2023,15(1):85-91.
[2] HESSMANN E, SCHNEIDER G.New insights into pancreatic cancer: Notes from a virtual meeting[J].Gastroenterology,2021,161(3):785-791.
[3] MIZRAHI J D, SURANA R, VALLE J W, et al.Pancreatic cancer[J].Lancet,2020,395:2008-2020.
[4] CAI J, CHEN H, LU M, et al.Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J].Cancer Lett,2021,520:1-11.
[5] KOLTAI T, RESHKIN S J, CARVALHO T M A, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: A physiopathologic and pharmacologic review[J].Cancers (Basel),2022,14(10):2486.
[6] 陈诗,赵玥,王振,等.山慈菇药理作用及临床应用研究进展[J].中华中医药学刊,2023,41(6):247-250.
[7] 魏巍,王冰瑶.莪术及其主要成分的药理作用研究进展[J].药物评价研究,2022,45(10):2154-2160.
[8] 王宏伟,田欣圆,于蕾.山慈菇的化学成分及其抗肿瘤作用机制研究进展[J].内蒙古医科大学学报,2022,44(3):305-309.
[9] 杜星锴,何俊,王宇.莪术抗肿瘤活性成分的网络药理学研究[J].华西药学杂志,2022,37(3):257-262.
[10] RU J, LI P, WANG J, et al.TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J].J Cheminform,2014,6:13.
[11] KIM S, CHEN J, CHENG T, et al.PubChem 2019 update: improved access to chemical data[J].Nucleic Acids Res,2019,47(D1):D1102-D1109.
[12] DAINA A, MICHIELIN O, ZOETE V.SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules[J].Nucleic Acids Res,2019,47(W1):W357-W364.
[13] UNIPROT CONSORTIUM T.UniProt: the universal protein knowledgebase[J].Nucleic Acids Res,2018,46(5):2699.
[14] STELZER G, ROSEN N, PLASCHKES I, et al.The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses[J].Curr Protoc Bioinformatics,2016,54:1301-13033.
[15] AMBERGER J S, BOCCHINI C A, SCHIETTECATTE F, et al.OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders[J].Nucleic Acids Res,2015,43(Database issue):D789-D798.
[16] WANG Y, ZHANG S, LI F, et al.Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics[J].Nucleic Acids Res,2020,48(D1):D1031-D1041.
[17] SZKLARCZYK D, MORRIS J H, COOK H, et al.The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J].Nucleic Acids Res,2017,45(D1):D362-D368.
[18] 姜玲,高马欣瑶,陈涛,等.中医药治疗胰腺癌机制研究进展[J].辽宁中医药大学学报,2023,25(4):59-63.
[19] 余思敏,唐人彦,张秀梅,等.刘鲁明治疗胰腺癌腹水处方策略[J].中华中医药杂志,2022,37(7):3881-3884.
[20] 张依婷,沈敏鹤,阮善明.沈敏鹤治疗胰腺癌经验浅析[J].浙江中医药大学学报,2022,46(1):82-85.
[21] 陈月,邓宏,黄杰,等.刘伟胜教授辨治胰腺癌临证思路[J].天津中医药,2021,38(2):180-184.
[22] 谭栋,郑康,梁刚,等.慈丹胶囊联合mFOLFOX6方案治疗Bismuth-Corlette Ⅱ型肝门部胆管癌的临床研究[J].现代药物与临床,2019,34(4):1084-1089.
[23] HERBERTS C, MURTHA A J, FU S, et al.Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer[J].Eur Urol,2020,78(6):834-844.
[24] WU S, ZHANG Q, ZHANG F, et al.HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity[J].Nat Cell Biol,2019,21(8):1027-1040.
[25] YANG B, FENG X, LIU H, et al.High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma[J].Oncogene,2020,39(42):6529-6543.
[26] LI N, YANG F, LIU D Y, et al.Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway[J].World J Gastrointest Oncol,2021,13(9):1164-1183.
[27] 徐新生. 莪术溃坚方对胰腺癌抑瘤作用及其机理研究[D].天津:天津医科大学,2014.